Premium
Treatment preferences and outcome in male hypogonadotropic hypogonadism: an Indian perspective
Author(s) -
Sanyal D.,
Chatterjee S.
Publication year - 2016
Publication title -
andrologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.633
H-Index - 59
eISSN - 1439-0272
pISSN - 0303-4569
DOI - 10.1111/and.12480
Subject(s) - hypogonadotropic hypogonadism , testosterone (patch) , fertility , human chorionic gonadotropin , medicine , regimen , gonadotropin , endocrinology , follicle stimulating hormone , hormone , luteinizing hormone , population , environmental health
Summary This retrospective study assessed treatment preferences and outcome with testosterone or HCG / HCG – FSH combination in Indian male idiopathic hypogonadotropic hypogonadism ( IHH ) subjects ( n = 31) above 18 years of age. 38.7% of IHH study subjects had no fertility plans and chose 3 monthly intramuscular testosterone undecanoate. 73.7% of subjects with fertility plans chose human chorionic gonadotropin ( HCG ) alone due to cost considerations. Spermatogenesis occurred in 21.4% on HCG alone and 60% of subjects on HCG with follicle‐stimulating hormone ( FSH ) combination. Treatment failure is higher than published Western rates. FSH and HCG combination regimen is costly but superior to HCG alone. However, treatment failure still persists, suggesting unknown testicular defect in IHH .